NNNS: Estimated and Acceptable Intake (2011)
Citation:
Study Design:
Class:
- Click here for explanation of classification scheme.
Quality Rating:
Research Purpose:
- To estimate the intake of the artificial sweeteners acesulfame-K, aspartame, cyclamate and saccharin by children (zero to 15 years of age) and adult male and female diabetics (types 1 and 2) of various ages (16 to 90 years) in Sweden
- Intakes were also compared to the Average Daily Intakes (ADI) set by the Joint FAO/WHO Expert Committee on Food Additives.
Inclusion Criteria:
- Members of the Association of Diabetics in the Stockholm area of Sweden
- The study population included women, men and children.
Exclusion Criteria:
None stated.
Description of Study Protocol:
- 1,120 diabetics were asked to complete a food frequency questionnaire about their sweetened food intake
- The response rate (71%, range of 59% to 78%) was comparable across age and gender groups.
Data Collection Summary:
Timing of Measurements
- Food frequency questionnaire was mailed with cover letter
- The questionnaire was formulated to extract information about participants' gender, age, height, weight, type of diabetes (1 or 2), how long had they been a diabetic and how long they had received treatment for diabetes
- The questionnaire also asked about the size and frequency of sweetened food intake.
Dependent Variables
- Average daily intake (ADI) of artificial sweeteners including acesulfame-K, aspartame, cyclamate and saccharin
- Intake of each sweetener was calculated using the average daily volume of each individual's consumption of the relative food items, divided by the participant's body weight
- This calculation was also made at the 10% and 5% levels among individual consumers in each group, in order to obtain the average consumption among high users for each category
- The individual food category averages were then multiplied by the maximum amount of sweetener that is allowed to be added to each specific item to determine the maximum exposure.
- Frequency of reading product content information.
Independent Variables
- Weight
- Height
- Medical treatment
- Consumption pattern of artificially sweetened foods: Cider and sugar syrup.
Description of Actual Data Sample:
- Initial N: 1,120 participants were asked to complete a questionnaire about their sweetener intake. The response rate (71%, range 59-78%) was comparable across age and gender groups
- Attrition (final N): 790 individuals responded to the questionnaire; 311 women, 235 men and 243 children
- Age: Children one to 15 years of age, adults 16 to 90 years old
- Ethnicity: Race was not mentioned, however participants were Swedish citizens.
- Other relevant demographics: Weight, height, medical treatment. No differences noted among groups.
- Anthropometrics: Weight
- Location: Stockholm, Sweden.
Summary of Results:
Average Daily Consumption of Sweeteners
- The food items that contributed most to the total intake of sweeteners were diet soda, cider, fruit syrup and table-top sweetener. Fruit syrup was the most important single source of intake.
- Table-top powder was high in children and was the most important single source of cyclamate for this age group
- The average intake for high-consumers among adult men and women (5% and 10% level) was, in almost all cases, below the ADI and often far below it
- The calculated intake of sweeteners in fruit syrup for children (5% level) was close to or exceeded the ADI for acesulfame-K (146% of ADI), aspartame (94%), cyclamate (227%) and saccharin (100%)
- With the exception of yogurt, no food item contributed more than 10% relative to the intake from fruit syrup.
Intake of Sweeteners From Beverages
- Acesulfame-K: Children at the 10% and 20% levels consumed 169% and 124% of the ADI, respectively
- Aspartame: Children at the 10% and 20% levels consumed 109% and 80% of the ADI, respectively
- Cyclamate: Children at the 10% and 20% levels consumed 263% and 193% of the ADI, respectively. In women, the corresponding value at the 10% individual level was close to the ADI at 101%.
- Saccharin: The only value that exceeded the ADI was at the 10% individual level in children, where the intake was 116% of the ADI.
Total Intakes of Beverages and Table Powder Combined
- Acesulfame-K: Not used in Sweden as a table-top powder
- Aspartame: Children at the 10% level exceeded the ADI at 114%
- Cyclamate: Children at the 10% and 20% levels consumed 317% and 231% of the ADI, respectively. Women exceeded the ADI at the 10% level (110% of ADI), whereas the intake at the 20% level was at 77%.
- Saccharin: Children at the 10% level were estimated to exceed the ADI at 126%.
Author Conclusion:
- The eight most consumed foodstuffs were diet soda, cider, fruit syrup, table powder, table tablets, table drops, ice cream, chewing gum, throat lozenges, sweets, yogurt and vitamin C
- The major sources of sweetener intake were beverages and table powder
- About 70% of the participants, equally distributed across all age groups, read the manufacturer's specifications of the food products' content
- The estimated intakes showed that neither men nor women exceeded the Average Daily Intake (ADI) for acesulfame-K. However, using worst-case calculations, high intakes were found in young children (169% of ADI).
- In general, the aspartame intake was low
- Children had the highest estimated (worst-case) intake of cyclamate (317% of ADI)
- Children's estimated intake of saccharin only slightly exceeded the ADI at the 5% level for fruit syrup
- Children had an unexpectedly high intake of table-top sweeteners, which in Sweden, is normally based on cyclamate.
Funding Source:
Government: | National Food Administration (Sweden) |
University/Hospital: | Uppsala University |
Reviewer Comments:
It was not possible to recreate all of the bar charts that were presented in this paper.
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | Yes | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | No | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | Yes | |
3. | Were study groups comparable? | Yes | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | Yes | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | ??? | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | N/A | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | Yes | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | Yes | |
4.1. | Were follow-up methods described and the same for all groups? | N/A | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | Yes | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | N/A | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | Yes | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | N/A | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | Yes | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | Yes | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | N/A | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | Yes | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | N/A | |
6.6. | Were extra or unplanned treatments described? | N/A | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | Yes | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | N/A | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | N/A | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | Yes | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |